Skip to content

Alnylam Pharmaceuticals

US · ALNY #627 by market cap Listed 1970
143.82 -4.00 -2.71%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 148.33 +0.35%
After-hours 144.50 +0.47%
Overnight 152.50 +3.17%
323.50143.82143.822026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ALNY?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -52.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 4.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall B+

The radar needs all six factors. Available grades are shown below.

Valuation C+

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 7.5x Better than 91%
Forward P/E 20.2x Better than 36%
Price / Sales 3.8x Better than 31%
P/E vs own 5-yr range 79th pctl Better than 27%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability A

How much profit the business keeps from each dollar of sales and capital.

Gross margin 81.6% Better than 91%
Operating margin 13.5% Better than 61%
Net margin 8.4% Better than 55%
Return on equity 73.3% Better than 96%
Return on invested capital 26.3% Better than 94%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -39.1% Better than 11%
6-month return -51.6% Better than 7%
12-month return (ex latest month) -48.7% Better than 3%
Distance below 52-week high 70.0% Better than 6%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.8x Better than 70%
Debt to assets 25.7% Better than 48%
Interest coverage 2.3x Better than 39%
Free cash flow / net income 148.3% Better than 65%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 76.0% Better than 56%
Upside to average target 106.9% Better than 85%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -12.86%
1M -37.66%
3M -37.28%
6M -51.82%
YTD -63.83%
1Y -67.74%
3Y -12.97%
5Y -20.54%

Key statistics

Price & volume

Prev close
147.82
Open
148.35
Day range
143.40 - 151.41
Avg price
146.44
Volume
2.33M
Turnover
340.96M
Amplitude
5.42%
52-week range
143.40 - 479.79

Valuation

P/E
61.73
P/E (TTM)
7.48
P/B
5.35
EPS
2.33
Net profit
312.07M
Net assets
3.60B

Share structure

Market cap
19.26B
Float cap
19.22B
Shares out
133.94M
Float shares
133.64M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 0% of range
143.40 479.79

70.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-201.87M net over the window

Short interest

Shares short
5.47M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Alnylam Pharmaceuticals (ALNY)?

Alnylam Pharmaceuticals last traded at 143.82. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Alnylam Pharmaceuticals's market cap?

About 19.26B.

What is the P/E ratio of Alnylam Pharmaceuticals?

The trailing twelve-month P/E is 7.48, below its own 5-year average of 19.64 — toward the top of its historical range (78.79% percentile). See the Valuation tab for the full history.

Does Alnylam Pharmaceuticals pay a dividend?

Alnylam Pharmaceuticals does not currently pay a regular dividend.

Is Alnylam Pharmaceuticals a buy according to analysts?

The consensus of 25 analysts is a Buy rating, with an average 12-month price target of 297.59, which implies 106.9% upside from the current price. This is not investment advice.

What is Alnylam Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Alnylam Pharmaceuticals a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Alnylam Pharmaceuticals discussion 0 comments

Add a comment